Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Bioage Labs Inc.
Headquarters: Richmond, CA, United States of America
Website: https://bioagelabs.com/
Year Founded: 2015
Status: Public
Industry Sector: HealthTechnology
CEO: Kristen Fortney, PhD
Number Of Employees: 64
Enterprise Value: $-138,073,286
PE Ratio: -1.66
Exchange/Ticker 1: NASDAQ:BIOA
Exchange/Ticker 2: N/A
Latest Market Cap: $121,890,000
BioCentury | Nov 15, 2024
Product Development
Pharmas challenging Novo and Lilly in obesity
An analysis of which major pharmas are in, out, or still deciding whether to take on obesity heavyweights Eli Lilly and Novo Nordisk
BioCentury | Oct 1, 2024
Product Development
Schizophrenia and sickle cell drugs, D.C. update: a BioCentury podcast
A first-in-class approval for BMS. A Pfizer withdrawal. ODAC & PD-L1. Congress’ unfinished business. BioAge’s NASDAQ IPO
BioCentury | Sep 27, 2024
Finance
Wave financing, BioAge IPO help biotech end September strong
In BioCentury’s latest Public Equity Report, Wave raises $200M on standout DMD data and BioAge marks fourth NASDAQ IPO this month
BioCentury | Sep 20, 2024
Finance
Upstream enters IPO queue; Nuvalent follow-on balloons to $575M
Also in BioCentury’s weekly Public Equity Report: Ascendis follows up a data release with a $300M offering; BioAge proposes terms for listing
BioCentury | Sep 6, 2024
Finance
Public Equity Report: After stock bump from new data, Vaxcyte raises $1.5B
Plus: BioAge is latest to join IPO queue; pain company Semnur going public via SPAC; and Jazz’s notes offering
BioCentury | Sep 4, 2024
Finance
Light from the IPO window
Six recent filings may mean appetite for new listings is on the rise
BioCentury | May 23, 2023
Management Tracks
Coelho succeeds Lankry as Gamida CFO
Plus: Sullivan becomes chief strategy officer at BioAge, and updates from Athira, Ambrx and FNIH
BioCentury | Oct 11, 2022
Product Development
Oct. 10 Quick Takes: WuXi Biologics clears one unit from U.S. watch list
Plus liver disease RNA company Ochre raises $30M, and updates from Supernus, RadioMedix, Hua, JW and scPharmaceuticals
BioCentury | Nov 18, 2021
Management Tracks
D’Amelio to retire as Pfizer’s CFO
Plus: BioAge, bit bio, Volastra, Provention and more
BioCentury | Apr 16, 2021
Finance
April 15 Quick Takes: Co-founded by Springer and Kruse, GPCR play Tectonic raises $80M; plus AltruBio, Rapha, Benchling, BioAge, Amgen
Tectonic Therapeutic Inc. debuted with an $80 million series A round co-led by Vida Ventures, T.A. Springer, and Polaris Partners to discover and develop of GPCR-targeted therapies. Tectonic was
Items per page:
1 - 10 of 11